USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: NEORX CORPORATION
Address: 410 W HARRISON ST
SEATTLE, WA 98119
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: (206) 281-7001

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $654,518.00 11
SBIR Phase II $1,857,331.00 4
STTR Phase I $100,000.00 1

Award List:

THE PURPOSE OF THIS PROJECT IS TO DEVELOP AND CHARACTERIZE MONOCLONAL ANTIBODIES WHICH CAN BE USED IN THE FORM OF RADIONUCLIDE IMMUNOCONJUGATES FOR IN VIVO IMAGING OF B-CELL LYMPHOMAS.

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: Robert w. schroff , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
The purpose of this project is to develop and characterize monoclonal antibodies which can be used in the form of radionuclide immunoconjugates for in vivo imaging of b-cell lymphomas. no monoclonal antibodies specific for human b-cell lymphomas or leukemias currently exist. such immunoconjugates… More

RADIORHENIUM ANTIBODIES FOR RADIOIMMUNOTHERAPY

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: Alan R. Fritzberg , Principal Investigator
Award Amount: $50,000.00

RADIOIODINATED CONJUGATES FOR THERAPY AND DIAGNOSIS

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: D. Scott Wilbur , Principal Investigator
Award Amount: $50,000.00

RADIOIODINATED CONJUGATES FOR THERAPY AND DIAGNOSIS

Award Year / Program / Phase: 1986 / SBIR / Phase II
Agency: HHS
Principal Investigator: D. Scott Wilbur , Principal Investigator
Award Amount: $500,000.00
Abstract:
The purpose of this contract proposal is to develop new radioiodine-labeled conjugates for monoclonal antibodies that can be used in diagnosis and therapy of cancer. the goal of our proposed research is to investigate a novel method of introducing high specific activity radioiodine into some small… More

RADIORHENIUM ANTIBODIES FOR RADIOIMMUNOTHERAPY

Award Year / Program / Phase: 1986 / SBIR / Phase II
Agency: HHS
Principal Investigator: Alan R. Fritzberg , Principal Investigator
Award Amount: $500,000.00
Abstract:
The objective of this phase i sbir project is to develop a re-186 agent suitable for labeling bifunctional chelating agent antibody conjugates. although chemically similar to tc-99m, application of re-186 to yield potential therapeutic radiopharmaceuticals presents problems which have yet to be… More

THE PURPOSE OF THIS PROJECT IS TO LABEL MONOCLONAL ANTIBODIES WITH ASTATINE-211 FOR USE IN RADIO-IMMUNOTHERAPY.

Award Year / Program / Phase: 1986 / SBIR / Phase I
Agency: HHS
Principal Investigator: D scott wilbur , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
The purpose of this project is to label monoclonal antibodies with astatine-211 for use in radio-immunotherapy.the goal of the proposed research is to develop a method to incorporate astatine into antibodies such that the astatine labile in vitro or in vivo. in the investigation, two different… More

THE OBJECTIVE OF THIS PHASE I PROJECT IS TO DEVELOP AND EVALUATE A NOVEL METHOD FOR RADIOLABELING MONOCLONAL ANTI- BODIES WITH TECHNETIUM-99M FOR THE SPECIFIC DIAGNOSIS OF CANCER.

Award Year / Program / Phase: 1986 / SBIR / Phase I
Agency: HHS
Principal Investigator: John m reno , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
The objective of this phase i project is to develop and evaluate a novel method for radiolabeling monoclonal anti- bodies with technetium-99m for the specific diagnosis of cancer. the method provides for a very efficient uptake of offered technetium to the high specific activity required for… More

RHENIUM-188 HAS FAVORABLE PHYSICAL PROPERTIES AS A THERA- PEUTIC RADIONUCLIDE, T-1/2 OF 17.

Award Year / Program / Phase: 1986 / SBIR / Phase I
Agency: HHS
Principal Investigator: Alan r fritzberg , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
Rhenium-188 has favorable physical properties as a thera- peutic radionuclide, t-1/2 of 17.0 hours, emax beta 2.2 mev,and egamma 155 kev. methodology has been developed for conjugation of rhenium in stable complexed form to antibodies. the objective of this proposal is to develop the technology… More

CONJUGATION OF SMALL RIBOSOMAL INHIBITORS TO ANTIBODIES

Award Year / Program / Phase: 1987 / SBIR / Phase I
Agency: HHS
Principal Investigator: Gowsala pavanasasivam phd
Award Amount: $50,000.00
Abstract:
Neorx corporation proposes a new series of small-molecular weight natural products that are similar to higher plant toxins in their mechanisms of action-inhibiting protein synthesis at the level of the ribosome. all inhibit in vivotranslation in cell-free systems. some are cytotoxic to eucaryotic… More

COLD STORAGE OF PLATELETS

Award Year / Program / Phase: 1997 / SBIR / Phase I
Agency: HHS
Principal Investigator: Tatalick, lauren m
Award Amount: $95,839.00

ALPHA RADIOTHERAPY VIA PRETARGETED LEAD 212

Award Year / Program / Phase: 1997 / SBIR / Phase I
Agency: HHS
Principal Investigator: Fritzberg, alan r
Award Amount: $100,000.00

ALPHA RADIOTHERAPY VIA PRETARGETED LEAD 212

Award Year / Program / Phase: 1998 / SBIR / Phase II
Agency: HHS
Principal Investigator: Fritzberg, alan r
Award Amount: $753,164.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase II
Agency: HHS
Principal Investigator: Alan R. Fritzberg
Award Amount: $104,167.00

N/A

Award Year / Program / Phase: 2000 / STTR / Phase I
Agency: HHS
Research Institution: University of Missouri
Principal Investigator:
Award Amount: $100,000.00
RI Contact: N/A

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Alan R. Fritzberg
Award Amount: $0.00

GEMCITABINE POTENTIATION OF PRETARGET RIT

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Donald B. Axworthy
Award Amount: $108,679.00
Abstract:
DESCRIPTION: Each year in the United States there are more than 20,000 deaths from pancreatic cancer. Gemcitabine is a cytarabine analogue that has been shown to be effective in prolonging the survival of patients with pancreatic cancer. Radiation therapy is also a mainstay… More